Samsung Bioepis Aims To Compete On Higher-Strength Humira In US

FDA Accepts sBLA For 100mg/ml Citrate-Free Version Of Hadlima Biosimilar

 
• By Dave Wallace
  
Dial High Black Red
Samsung Bioepis is targeting high-concentration adalimumab • Source: igor kisselev / Alamy Stock Vector

More from Biosimilars

More from Products